NASDAQ : UTHR
United Therapeutics Corporation — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 598.72 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 25.68B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 25.55B |
| Enterprise Value | 21.75B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 42.89M |
| Shares Outstanding | 42.89M |
| Shares Change (YoY) | -3.20% |
| Shares Change (QoQ) | -2.97% |
| Owned by Insiders (%) | 1.95% |
| Owned by Institutions (%) | 92.95% |
| Float | 39.21M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 21.31 |
| Forward PE | 21.08 |
| PS Ratio | 8.12 |
| Forward PS | 7.90 |
| PB Ratio | 3.99 |
| P/TBV Ratio | 4.08 |
| P/FCF Ratio | 23.44 |
| P/OCF Ratio | 15.20 |
| PEG Ratio | 3.21 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 16.64 |
| EV / Sales | 6.92 |
| EV / EBITDA | 14.58 |
| EV / EBIT | 15.53 |
| EV / FCF | 19.96 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.73 |
| Quick Ratio | 4.89 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 117.06 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 19.32% |
| Return on Assets (ROA) | 11.61% |
| Return on Invested Capital (ROIC) | 31.28% |
| Return on Capital Employed (ROCE) | 21.24% |
| Weighted Average Cost of Capital (WACC) | 6.94% |
| Revenue Per Employee | $2.25M |
| Profits Per Employee | $936,357 |
| Employee Count | 1,400 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 2.41 |
Taxes
| Measure | Value |
|---|
| Income Tax | 262.10M |
| Effective Tax Rate | 16.66% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.49 |
| 52-Week Price Change | +34.10% |
| 50-Day Moving Average | 528.79 |
| 200-Day Moving Average | 532.16 |
| Relative Strength Index (RSI) | 69.21 |
| Average Volume (20 Days) | 658,742 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.46M |
| Short Previous Month | 3.60M |
| Short % of Shares Out | 5.73% |
| Short % of Float | 6.27% |
| Short Ratio (days to cover) | 2.42 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 3.15B |
| Gross Profit | 2.72B |
| Operating Income | 1.40B |
| Pretax Income | 1.57B |
| Net Income | 1.31B |
| EBITDA | 1.50B |
| EBIT | 1.40B |
| Earnings Per Share (EPS) | $27.95 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.66B |
| Total Debt | n/a |
| Net Cash | 3.80B |
| Net Cash Per Share | $88.68 |
| Equity (Book Value) | 6.40B |
| Book Value Per Share | 149.97 |
| Working Capital | 2.88B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 1.69B |
| Capital Expenditures | -592.20M |
| Depreciation & Amortization | 91.50M |
| Net Borrowing | n/a |
| Free Cash Flow | 1.09B |
| FCF Per Share | $25.48 |
Margins
| Measure | Value |
|---|
| Gross Margin | 86.14% |
| Operating Margin | 44.53% |
| Pretax Margin | 49.87% |
| Profit Margin | 41.56% |
| EBITDA Margin | 47.43% |
| EBIT Margin | 44.53% |
| FCF Margin | 34.65% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 3.20% |
| Shareholder Yield | 3.20% |
| Earnings Yield | 4.69% |
| FCF Yield | 4.27% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $670.93 |
| Price Target Difference | 12.63% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 8.98% |
| EPS Growth Forecast (3Y) | 15.03% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 23, 2009 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 18.19 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |